Display Settings:

Format

Send to:

Choose Destination
    Cancer Prev Res (Phila). 2010 Jan;3(1):8-11.

    Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans.

    Source

    Department of Dermatology, UAB Skin Diseases Research Center and UAB Comprehensive Cancer Center, The University of Alabama at Birmingham, 35294-0019, USA. celmets@uab.edu

    Abstract

    Bailey et al. report in this issue of the journal (beginning on page 35) one of the first successful trials of basal cell carcinoma (BCC) prevention. Oral alpha-difluoromethyl-dl-ornithine (DFMO) reduced new BCCs in patients with a prior history of nonmelanoma skin cancer. DFMO is an inhibitor of ornithine decarboxylase, a key enzyme in the polyamine biosynthetic pathway. This perspective on Bailey et al. discusses our knowledge of the contribution of polyamines to BCC pathogenesis, how this knowledge advanced the development of a new method to prevent BCCs, and prospects for future studies of DFMO in BCC prevention.

    PMID:
    20051367
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2926793
    Free PMC Article

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk